Abstract submission guidelines



The abstracts can be submitted for:

  • Poster presentation
  • Nano-symposium: To propose that your abstract be grouped with others in the same poster session and have scheduled presentations, choose nanosymposium. A maximum of 6 posters can be included in a nanosymposium
  • Abstract-Symposium: to be selected only for symposium/session speakers


  • All abstracts must be submitted before April 1, 2019. Abstracts received after the deadline will not be considered.
  • All abstracts must contain original work.
  • The abstracts should be categorized according to the following topics:
    • Molecular mechanisms: genetics, genomics, epigenetics, other -omics
    • Molecular and cellular phenotypes: Neurodevelopment
    • Molecular and cellular phenotypes: Mitochondria, metabolism
    • Molecular and cellular phenotypes: Inflammation, immunity, autoimmunity
    • Animal models: Phenotyping
    • Preclinical models: Pharmacological/non-pharmacological interventions
    • Cancer/ Leukemia
    • Alzheimer’s disease in Down syndrome: Cellular and molecular mechanisms
    • Human studies: Neuropathology, neurodevelopment
    • Clinical studies: Cognition, intellectual disability, neuropsychology, language
    • Clinical studies: Biomarkers, neuroimaging, outcome measures
    • Clinical studies: Comorbidities (e.g. Psychiatric Disorders/Metabolic disorders/Sensory Disorders/Cardiovascular Diseases/other)
    • Clinical studies: pharmacological/non-pharmacological interventions
    • Alzheimer’s disease in Down syndrome: Human studies
    • Other
  • Abstracts should be written in English.
  • Abstracts should be strictly submitted through the on-line abstract submission platform once the registration to the congress is processed. The corresponding access to the abstract submission platform will be included on the Registration Confirmation letter. Abstracts sent by e-mail, fax, post, etc. will not be taken into consideration.
  • The content of the abstract is solely the responsibility of the author(s)
  • Each presenting author can present no more than 1 abstract.
  • The presenting author ensures that all the co-authors are aware of the abstract content before submitting the mentioned abstract.
  • The submission of an abstract acknowledges the author acceptance for the abstract to be published in the official book of abstracts
  • The body of the abstract must not exceed 300 words. This text limit does not include title, authors and affiliations.
  • The title must be capitalized.
  • Only standardized abbreviations will be allowed. Place special or unusual abbreviations in parentheses after the first time that the full word appears.
  • Abstracts should clearly state:
    • Background and objectives: state the rationale or hypothesis followed by objectives
    • Methods: briefly discuss the design of the study and how it was conducted
    • Results: present the main results with appropriate statistics/data analysis and pertinent discussion
    • Conclusions: limit the conclusions to those that are directly supported by the results
    • Keywords: include 3-5 keywords
  • Do not mention the names of the (co)authors in your abstract text since the reviewing will be handled anonymously. Abstracts with names of (co)authors in the abstract text can’t be reviewed and will be excluded.

Author names should be in the following format:

  • Last Name, Initials
  • Affiliations must also include the city and country (e.g. The Mount Sinai Hospital, New York, United States of America)

Reviewing & acceptance

  • Abstracts will be blind reviewed and selected by the Scientific Program Committee of the T21RS.
  • The Scientific Program Committee will select a limited number of abstracts to be included as short talks in the symposiums.
  • Authors will be notified by email whether their abstracts have been accepted or not no later than May 1, 2019. Confirmation of acceptance or rejection will be emailed to the corresponding address of the first author. Please contact the Technical Secretariat (t21rs2019@bcocongresos.com) if you do not receive a confirmation email.
  • Instructions for poster, nanosymposium presentations, and selected short talks will be sent in May, 2019.

Author Registration

  • The presenting author must be registered before submitting an abstract.
  • The link to access the abstract submission platform will be included in the registration confirmation letter.

For any further information concerning the abstract guidelines and presentations, do not hesitate to contact us t21rs2019@bcocongresos.com